Ticker

Deutsche Bank AG purchased a new position in Achieve Life Sciences, Inc. (NASDAQ: ACHV) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 77,485 shares of the biopharmaceutical company's stock, valued at approximately $506,000. Deutsche Bank AG

Closed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new Chief Executive Officer, experienced commercial, CMC, and quality leaders, along with six new appointments to the Board of Directors Anticipates potential FDA approval in the first half of 2027,…

SEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced the appointments of Ronald Dadino as Senior Vice President, Chemistry, Manufacturing and Controls…

SEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that Achieve's board of directors approved stock option grants to purchase an aggregate of 1,190,000 shares of its common…

Achieve Life Sciences, Inc. (NASDAQ: ACHV - Get Free Report) was up 6.5% during mid-day trading on Friday. The stock traded as high as $6.33 and last traded at $6.35. 209,257 shares were traded during trading, a decline of 84% from the average session volume of 1,329,049 shares. The stock had previously closed at $5.96.